Compare Avient Corporation (AVNT) vs Biogen Inc (BIIB) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Avient Corporation vs Biogen Inc — how do they compare? Avient Corporation trades at $35.98 (market cap $3.28B), while Biogen Inc trades at $195.5 (market cap $28.34B). The key difference: Biogen Inc is far larger — about 8.6× Avient Corporation's market cap, and Avient Corporation pays a 3.07% dividend while Biogen Inc pays none. Which is the better fit depends on your goals.
| AVNT | BIIB | |
|---|---|---|
Market Cap | $3.28B | $28.34B |
Sector | Technology | Health |
52-Week High | $43.28 | $216.63 |
52-Week Low | $27.48 | $122.68 |
Enterprise Value | $4.78B | $30.62B |
Dividend Yield | 3.07% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Avient Corporation (AVNT) trades at $35.57, down 1.28% with a bearish technical signal. The company shows consistent earnings beats with Q1 2026 EPS of $0.83 exceeding expectations. Fundamentals reveal a P/E of 20.79 and net income margin of 4.81%, while cash flow trends improved from -$34M in 2025 to -$28M projected for 2026. Recent developments include new product launches and ClassNK approval for Dyneema DM20 fiber, supporting growth in renewable energy markets.
AVNT presents a mixed outlook with strong analyst support (60% buy ratings) offset by near-term technical weakness. The company's innovation pipeline and cost control measures provide upside potential, though macroeconomic headwinds and competitive pressures remain key risks. Earnings growth and successful market expansion of new technologies are critical catalysts for stock performance.
Biogen (BIIB) trades at $209.03, up 4.96% today, with a bullish technical signal and strong analyst support. Recent quarterly earnings have consistently beaten expectations, and the company maintains solid profitability with a 75.49% gross margin. Key developments include FDA approval for a subcutaneous starter dose of Leqembi and promising Phase 2 data for its Alzheimer's drug diranersen, driving positive sentiment.
The outlook is positive, with a consensus price target of $230.18 suggesting upside. Investment opportunities lie in Alzheimer's pipeline advancements, but risks include clinical trial outcomes and competitive pressures. Revenue stability and cost management support fundamentals, though regulatory hurdles remain a watchpoint.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Avient Corporation
Avient Corporation is a global leader in specialized and sustainable material solutions. Formed from the legacy of PolyOne and Clariant’s masterbatch business, it provides highly engineered polymer formulations, color systems, and advanced composites that enhance the performance and sustainability of products in industries like healthcare, defense, and consumer packaging.
Read more on AVNT →About Biogen Inc
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.
Read more on BIIB →
